Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Allele Biotech

Request full access

Private, san diego-based company

San Diego, United StatesFounded 1999Biotech & Life Sciences

About Allele Biotech

Allele Biotechnology and Pharmaceuticals, Inc. operates as a Contract Development and Manufacturing Organization (CDMO) and a key supplier of molecular biology reagents, positioning itself at the intersection of research tools and therapeutic development. Founded in 1999 by Dr. Jiwu Wang, a biochemist with a Ph.D. from the University of Southern California and extensive experience in molecular biology, the company leverages its scientific roots to serve biomedical researchers and pharmaceutical partners. Dr. Wang's research background in pre-mRNA splicing and his numerous patents in RNA interference, imaging, and stem cell production have fundamentally shaped the company's trajectory.

The company's business model is multifaceted, generating revenue through the sale of proprietary research products, technology licensing, and offering comprehensive CDMO services. Its client base ranges from academic researchers to large pharmaceutical companies like Astellas. A cornerstone of Allele's offerings is its induced Pluripotent Stem Cell (iPSC) technology. The company has developed patented, feeder-free methods using messenger RNA (mRNA) to create clinical-grade iPSC lines, which are crucial for developing cell therapies for conditions such as diabetes and spinal injuries. Allele established a cGMP-compliant facility in San Diego to produce and bank these iPSC lines, offering both off-the-shelf and custom cell line development.

Another significant area of operation is the development of single-domain nanoantibodies (nAbs) derived from camelids. These small, highly stable antibodies offer advantages in specificity and tissue permeability, making them suitable for diagnostics and as biologics in immunology and oncology. Allele's involvement in this field dates back to 2008. Furthermore, the company is known for its high-performance fluorescent proteins, most notably mNeonGreen, which is considered one of the brightest monomeric fluorescent proteins available and is used extensively in biomedical imaging and research. The intellectual property surrounding mNeonGreen led to patent infringement lawsuits against major pharmaceutical companies for its unauthorized use in COVID-19 research. During the COVID-19 pandemic, Allele utilized its iPSC and nanoantibody platforms to develop diagnostics and therapeutic candidates.

Source: Dealroom company data

At a glance

Status
Operational
Employees
26
Open positions
None listed
Dealroom signal
72.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, DNA, Genetics and genomics, Packaging and Containers, Spinout, Genome Engineering, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANT✓Other financing Oct 2018 — — National Institute of General Medical Sciences —
SERIES B✓Equity / VC Oct 2016 $11M $44M Undisclosed —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Allele Biotech website traffic

Latest recorded traffic for Allele Biotech is 1.9K monthly website visits, down 47.2% over the last three months. Allele Biotech's team grew 0% over the past year.

Latest monthly visits1.9K 3-month web change-47.2% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Allele Biotech in the San Diego ecosystem

Live from Dealroom

The Allele Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • National Institute of General Medical Sciences

Series A2 investors entered at this stage

  • Yuan Capital
  • Eric Xu

Other known investors1 additional known investor

  • University of California, San Diego
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Diego HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Allele Biotech on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Allele Biotech’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.